KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Retained Earnings (2018 - 2025)

Historic Retained Earnings for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$1.7 billion.

  • Esperion Therapeutics' Retained Earnings fell 669.94% to -$1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year decrease of 669.94%. This contributed to the annual value of -$1.6 billion for FY2024, which is 333.99% down from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Retained Earnings is -$1.7 billion, which was down 669.94% from -$1.7 billion recorded in Q2 2025.
  • Esperion Therapeutics' Retained Earnings' 5-year high stood at -$928.2 million during Q1 2021, with a 5-year trough of -$1.7 billion in Q3 2025.
  • For the 5-year period, Esperion Therapeutics' Retained Earnings averaged around -$1.4 billion, with its median value being -$1.5 billion (2023).
  • In the last 5 years, Esperion Therapeutics' Retained Earnings plummeted by 4977.13% in 2021 and then plummeted by 333.99% in 2024.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Retained Earnings stood at -$1.1 billion in 2021, then fell by 21.12% to -$1.3 billion in 2022, then fell by 15.62% to -$1.5 billion in 2023, then dropped by 3.34% to -$1.6 billion in 2024, then fell by 5.28% to -$1.7 billion in 2025.
  • Its Retained Earnings stands at -$1.7 billion for Q3 2025, versus -$1.7 billion for Q2 2025 and -$1.6 billion for Q1 2025.